Weight Loss Medicines for Diabetes: Why Some Treatments Affect Weight

• Explains which diabetes medicines are associated with weight loss, which with gain, and the mechanism behind each.
• Covers the licensing position for type 1 diabetes honestly, including what changed and why.
• Flags the interaction and the hypoglycaemia risk that a weight loss consultation must catch in anyone with diabetes.
• Online consultation with UK registered prescribers, from a GPhC registered pharmacy, if you want your options reviewed clinically.

Some diabetes medicines cause weight loss, some cause weight gain, and a few do neither. That is not a design feature. It follows from how each one lowers blood glucose.

Understanding which is which matters more than it sounds, because it changes what a realistic weight goal looks like and it explains why two people with the same condition can have opposite experiences on treatment.

This page sets out the direction of effect by drug class, explains where licensed weight management medicines fit alongside diabetes treatment, and covers type 1 diabetes separately, because the position there is genuinely different.

Key things to know

• Insulin, sulfonylureas and pioglitazone are associated with weight gain. Metformin and DPP-4 inhibitors are broadly weight neutral. SGLT2 inhibitors and GLP-1 receptor agonists are associated with weight loss.
• Type 2 diabetes counts as a weight related condition in the licences for weight management medicines, so the two treatment areas overlap.
• Prediabetes, described clinically as dysglycaemia, also appears as a weight related condition in some of those licences.
• No weight management medicine is licensed in the UK for type 1 diabetes. That is not a technicality, and it is the reason this group needs specialist input.
• Dapagliflozin was the only SGLT2 inhibitor licensed here for type 1 diabetes. That authorisation was withdrawn in December 2021.
• NICE advises that GLP-1 receptor agonists and tirzepatide should not be prescribed alongside a DPP-4 inhibitor.
• If your appetite falls but your insulin or sulfonylurea dose does not change, you can become hypoglycaemic. This needs planning, not discovering.

Why do some diabetes medicines affect weight?

The weight effect follows the mechanism. Medicines that lower glucose by increasing insulin, whether by injecting it or by prompting the body to release more, tend to cause weight gain. Medicines that lower glucose by removing it from the body or by reducing how much you eat tend to cause weight loss.

That single principle explains almost the whole picture, and it is worth knowing because it means the weight effect is predictable rather than random.

Ozempic is a GLP-1 agonist used in diabetes care that can also aid weight loss. Tirzepatide works through both GIP and GLP-1 pathways to support weight reduction.

Two caveats on that table. These are average directions of effect, not guarantees, and effectiveness varies between individuals and also depends on dosage. And the weight effect is one consideration among several, alongside glucose control, kidney and heart benefits, hypoglycaemia risk and how a medicine suits your life.

Does weight gain on diabetes treatment mean it is not working?

Usually the opposite. Weight gain after starting insulin often reflects treatment working, because glucose that was previously being lost in the urine is now being used and stored instead.

That is a genuinely difficult thing to be told, particularly for someone who was losing weight before diagnosis because of uncontrolled glucose. It is worth raising with your diabetes team rather than solving alone, because there are usually options within the treatment plan.

Never reduce or skip a prescribed diabetes medicine to influence your weight.

One effect of metformin that is not about weight

Long term metformin use is associated with reduced vitamin B12 levels, and the MHRA advises monitoring B12 in people taking it long term, particularly those with risk factors or symptoms of deficiency.

This belongs on a page about weight because the symptoms overlap so neatly. Low B12 causes fatigue, breathlessness, pins and needles and poor concentration, all of which are easy to attribute to eating less, to diabetes itself, or to simply getting older.

If you take metformin long term and you are persistently tired, do not assume it is the diet. Raise it, because it is specific and correctable.

Weight loss medicines and type 2 diabetes

Licensed weight management medicines can be appropriate for people with type 2 diabetes, and the two treatment areas overlap more than in any other group.

The licences for these medicines are written around BMI thresholds plus weight related health conditions, and type 2 diabetes is one of those conditions. Someone with type 2 diabetes may therefore meet the criteria at a lower BMI than someone without it.

There is a second overlap. Some of the same active ingredients are licensed separately for type 2 diabetes and for weight management, as different products at different strengths. They are not interchangeable, and a prescriber choosing between them is making a clinical decision rather than a naming one.

The interaction a weight loss consultation must catch

NICE advises that GLP-1 receptor agonists and tirzepatide should not be prescribed alongside a DPP-4 inhibitor. This matters enormously for anyone with type 2 diabetes seeking weight management treatment privately.

The scenario is easy to picture. Someone is already taking a DPP-4 inhibitor for their diabetes, seeks weight loss treatment elsewhere, and does not think to mention a tablet they have taken for years. Both act on related pathways, and combining them is advised against.

The same risk applies to duplication. If your diabetes treatment already includes a GLP-1 receptor agonist, adding a weight management product containing the same class means taking two of the same thing.

This is the practical reason a weight loss assessment must include your full medicine list, and why a form that does not ask for it is not doing its job.

What happens to your diabetes medicines if you lose weight

They often need adjusting, and this should be planned rather than discovered.

Losing weight improves insulin sensitivity, which means the dose of glucose lowering medicine that was right at the start may become too much. That is a good problem, but it needs monitoring, and it is one of the main reasons this group should not be managed in isolation from their diabetes care.

Your prescriber will determine the appropriate treatment. Treatment suitability depends on an individual clinical assessment, and these medicines should only be used under the supervision of an appropriately qualified prescriber.

Weight loss medicines and prediabetes

Prediabetes, described clinically as dysglycaemia, appears as a weight related condition in the licences for some weight management medicines, alongside conditions such as high blood pressure and sleep apnoea.

That means someone with prediabetes may meet the eligibility criteria at a BMI where someone without it would not, provided the other criteria are also met.

This is worth knowing because prediabetes is the point at which weight change has the most leverage. NICE describes a loss of 5% to 10% of body weight over three to six months as a clinically meaningful goal, and that range is roughly where improvements in blood glucose control begin to appear.

Whether medication is appropriate at that stage is still an individual clinical decision, and lifestyle change remains the foundation of it.

Weight loss medicines and type 1 diabetes

No weight management medicine is licensed in the UK for use in type 1 diabetes. That is the honest answer, and it is the most important thing on this page.

The licensed weight management medicines were tested and authorised in populations that did not include people with type 1 diabetes. Their licences are written around BMI and weight related conditions, and type 1 diabetes is not one of those conditions in the way type 2 is.

Weight is a real issue for many people living with type 1 diabetes, and saying so is not the same as saying nothing can be done. It means that anything considered in this group is a specialist decision made with your diabetes team, with monitoring in place, rather than something arranged through a routine online consultation.

Why SGLT2 inhibitors are no longer licensed for type 1 diabetes

Dapagliflozin was the only SGLT2 inhibitor authorised in the UK for type 1 diabetes. In December 2021 the MHRA confirmed it was no longer authorised for that use.

The background is a raised risk of diabetic ketoacidosis in people with type 1 diabetes taking this class of medicine. Diabetic ketoacidosis is a serious complication in which acid builds up in the blood, and it requires urgent hospital treatment.

The MHRA has also warned that ketoacidosis in people taking SGLT2 inhibitors can present atypically, with blood glucose near normal rather than very high. That is the dangerous part, because a normal looking glucose reading can delay recognition. SGLT-2 inhibitors may also carry an increased risk of foot infections, which is one reason specialist oversight matters in type 1 diabetes. Guidance is to test blood ketones in anyone with symptoms of ketoacidosis even when glucose is near normal.

What to do if you have type 1 diabetes and want to lose weight

Start with your diabetes team rather than with a weight loss service. That is not a deflection, it is where the useful options are.

Weight management in type 1 diabetes involves balancing food, activity and insulin together, and changing one without the others causes problems; nutrition planning often focuses on lower carbohydrates and higher fiber. Increased physical activity can support weight loss while helping preserve muscle mass. A team that already knows your insulin regimen, your glucose data and your history can adjust all three. A service that sees only your weight cannot.

If you contact any weight loss service, say at the very start that you have type 1 diabetes. It should change the conversation immediately, and if it does not, that tells you something about the service.

Hypoglycaemia: the risk that changes everything

If your appetite falls but your glucose lowering medicine does not change, your blood sugar can drop too low. This is the single most common practical problem when weight management and diabetes treatment meet.

The medicines that carry this risk are insulin and sulfonylureas, both of which lower glucose regardless of how much you have eaten. Adding an appetite reducing medicine, or making a substantial dietary change, alters the equation without altering the dose. GLP-1 receptor agonists can also increase the risk of severe hypoglycemia when used alongside medicines that already cause hypoglycaemia.

Symptoms of low blood glucose include shaking, sweating, feeling anxious or irritable, hunger, difficulty concentrating, confusion and, if it continues, loss of consciousness. Anyone taking insulin or a sulfonylurea should know these known side effects and should have their usual treatment for hypoglycaemia to hand.

The practical point is that this needs planning before you start anything, not managing after it happens. Tell whichever healthcare professional is prescribing your weight management treatment exactly what diabetes medicines you take, and make sure your healthcare team knows about the weight treatment.

What should be monitored, and when

Combining weight management with diabetes treatment increases what needs watching, and knowing the list in advance makes the process easier to follow.

Glucose monitoring usually needs to be more frequent when anything changes, because both a new medicine and a substantial change in eating will move your readings. If you use a meter or a sensor, this is the period to use it more rather than less.

Beyond glucose, a review would typically consider your longer term glucose control, kidney function, blood pressure, and whether existing glucose lowering doses still fit. Weight and waist measurement sit alongside those rather than replacing them.

Two things are worth raising proactively rather than waiting to be asked: any low blood glucose episodes since the change, and any symptoms that started when a treatment did. Both are more useful to a prescriber than a weight number.

Insulin and weight

Insulin is associated with weight gain, and pretending otherwise helps nobody. It is also the treatment that keeps people with type 1 diabetes alive, and there is no version of good care that involves less of it than you need.

Some weight gain after starting or intensifying insulin reflects glucose being retained and used rather than lost in urine. Some reflects eating to prevent or treat low blood glucose. The second of those is often more addressable than people realise, because it can point to a dose or timing that needs adjusting.

There is one thing worth saying plainly. Some people with diabetes are tempted to change or skip insulin because of its effect on weight. This is dangerous and it is more common than most people assume. If that thought has occurred to you, tell your diabetes team. It is a recognised issue, there is specific support for it, and they will have heard it before.

What to tell any prescriber

Whether you are speaking to your diabetes team or a weight management service, the same information changes the decision.

1. Which type of diabetes you have. Type 1 and type 2 lead to different answers, and this is the first thing that should be asked.
2. Every diabetes medicine you take. Include tablets you have taken for years and forget about, since those are exactly the ones that cause interaction problems.
3. Every other medicine and supplement. Including anything bought over the counter or online.
4. Whether you have had low blood glucose episodes. Their frequency and severity change what is safe.
5. Any history of ketoacidosis. This is directly relevant to what can be considered.
6. Whether you are pregnant, breastfeeding or planning pregnancy. Both diabetes and weight management treatment change in that context.

If a service does not ask most of these before supplying anything, that is a reason to stop rather than a convenience.

When to seek urgent medical advice

Some symptoms need urgent attention rather than a phone call tomorrow.

Seek urgent medical attention if you have:

• Nausea or vomiting with stomach pain, excessive thirst, fast or deep breathing, unusual sleepiness or confusion, which can indicate ketoacidosis, even if your glucose reading looks normal
• A sweet smell to your breath, or a sweet or metallic taste in your mouth
• Repeated low blood glucose episodes, or an episode you needed help to treat
• Persistent vomiting or an inability to keep fluids down
• Severe abdominal pain

Arrange a review, without waiting weeks, if you have unintended weight loss, glucose readings that have changed pattern since starting a new medicine, or symptoms that started when a treatment did.

Where a clinical assessment fits

If you have diabetes and are considering weight management treatment, an assessment is the step that matters, and it should involve the people who manage your diabetes.

An online consultation with UK registered prescribers covers your medical history, your full medicine list, your BMI and any weight related conditions, and establishes whether treatment is appropriate before anything is supplied. In line with National Institute guidance and standards for health and care excellence, a healthcare professional will also consider your glucose monitoring and how existing medicines may need adjusting, with your wider healthcare team involved where needed to support care excellence. In the UK, orlistat can be prescribed by your GP, while Wegovy and Saxenda require specialist weight management services. Mounjaro is being rolled out in England over 12 years, so access may depend on your local stage and service pathway.

Some people are assessed and found not to be suitable. For type 1 diabetes in particular, the appropriate route is specialist input rather than a routine consultation, and being told that is the process working.

Medical Disclaimer

This article is for general information and does not replace individual medical advice. It does not diagnose any condition, recommend a specific treatment for you, or compare or rank medicines against one another.

Never stop, reduce or change prescribed diabetes drugs without advice from your prescriber or diabetes team. Treatment suitability depends on an individual clinical assessment by an appropriately qualified healthcare professional, who will consider your medical history and current medicines. Prescription medicines should only be used under the supervision of an appropriately qualified prescriber, and never take one that was not prescribed for you. If you miss a dose, follow the patient information leaflet supplied with the medicine, and do not take a double dose to make up for it. Tirzepatide has known side effects, and nausea was reported by 75% of users in one study. Report suspected side effects through the MHRA Yellow Card scheme.

Results vary between individuals. If you have any of the urgent symptoms above, seek medical attention immediately.